The perfonnance of different solid-phase luminescence immunoassays has been documented using four different assay concepts. These are CELIA (chemilüminescence immunoassay), SPALT (solid-phase antigen luminescence technique), ILMA (immunoluminometric assay) and ILSA (immunoluminometric labelled second-antibody assay). CELIA is analogous to a solid-phase radioimmunoassay and uses a labelled antigen, SPALT and ILSA use a labelled second (species-specific) antibody and ILMA a labelled substancespecific antibody, i.e. analogous to the immunoradiometric assay. Both bioluminescent and chemiluminescent labels have been used. Pyruvate kinase was used for bioluminescence and diazoluminol and N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide for chemilüminescence. Relevant quality-control parameters and reference ranges have been given for the optimised assays. Assays described are: thyroxine, thyroxine binding globulin, Cortisol, caeruloplasmin, ferritin and Oreactive protein.
Introduction
This third and final part of a study upon solid phases for immunoassay describes the assays which have been developed from the experiments described in the first two parts (l, 2). Both functional and nonfunctional assay Systems have been presented äs well äs comparisons between different assay Systems for the same analyte.
The assays described include those using labelled antigens and labelled first or second antibodies. The labels used are: diazoluminol and N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide, the latter being coupled via an active ester of N-hydroxysuccinamide. The synthesis of the labels has already been described (2) . The assays represent different analytes (haptens or peptides) and methods. Where applicable, assays which have already been introduced into the routine laboratory are presented with relevant quality-control parameters and comparisons with the methods which they have replaced.
Materials and Methods

Materials
Antibodies
Antibodies to human liver and spieen ferritins were purchased from Atlanta (Pelfreez), Heidelberg; Proma (Seward), Augsburg; Boehringer-Ingelheim (DAKO), Ingelheim; these being the distributors in the FRG. Antibodies to human C-reactive protein and human thyroxine binding globulin were obtained from Proma and Boehringer-Ingelheim.
Antibodies to caeruloplasmin were purchased from Behringwerke, Marburg a. d. L., FRG, whereas those for Cortisol and thyroxine were donations from Dr. Mario Pazzagli, Firenze, Italy and the Fa. Henning Berlin GmbH respectively. Donkey anti-rabbit IgG was purchased from Wellcome Diagnostika, Burgwedel, FRG and rabbit anti-sheep IgG from Boehringer Ingelheim.
Standard materials
Ferritin Standards were obtained from Travenol-Clinical Assays, Munich, FRG, C-reactive protein serum Standard from Behringwerke, thyroxine and Cortisol Standards from Henning Berlin and Diagnostic Products Corporation (Hermann Biermann, Bad Nauheim, FRG) respectively. Human transferrin was purchased from Behringwerke, human caeruloplasmin from Serva, Heidelberg, FRG or Sigma, Munich, human thyroxine binding globulin being a gift from Prof. K. Hörn and Dr. R. Gärtner, Munich.
Equipment
The luminometers used were either the LKB-1251 (LKB Instruments, Gräfelfing, FRG) or the LB-950 (Laboratorium Prof. Dr. Berthpld, Wildbad, FRG). The LKB-1251 was a 25-sample semiautomatic Instrument with microprocessor, the LB-950 had a 300 sample capacity and was also microprpcessor controlled. Both instruments were at the time of the experiments not able to process data fully so that an off-line data-processing with a desk-top comp uter (CBM 8032 -Commodore Business Machines, Neu-Isenbürg, FRG) and spline function Programme was necessary.
Methods
CELIA -chemiluminescent immunoassay
This type of assay is analogous to a solid-phase radioimmunoassay in which the first antibody was coupled to a polystyrene ball (1) and in which the tracer was an antigen labelled with N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide instead of a radioactive marker. Table l Incubate äs above and wash with 2 x l ml 0.15 mol/1 NaQ containing 0.15 ml/l Tween 20. Transfer balls to measuring euvettes and load luminometer.
The light initiation Step is identical with that shown in table 2.
* The diazotisation was analogous to the methpd described in Lc.
(2), replacing the second antibody with thyroxine binding globulin. The dilution factor given here is the further dilution of the TBG-diazoluminol. The amount of label added to each tube was approximately 100 ng.
ILMA -immunoluminometric assay
The ILMA is analogous to the IRMA (immunoradiometric assay) (3) and is especially suited for assays where the antigen is either unavailable or prohibitively expensive so that a SPALT (see bel ow) assay is out of the question. Several antibody-pairs were tested until a suitable combination was found. Table 2 shows an assay flow sheet for a ferritin ILMA.
ILSA -immunoluminometric labelled second^antibody assay
The ILSA is identical with the ILMA, but with one exception, and that is that a labelled second antibody is used in addition to the two substance-specific antibodies used in the ILMA. This assay was only used in cases where diazoluminol was used for labelling the antibodies, in Order to achieve maximal sensitivity. Table 3 shows a flow sheet for a C-reäctive protein ILSA. Incubate for 60 min on horizontal rotator and wash with l ml wash buffer followed by l ml 0.15 mol/1 NaCl. Transfer balls to measuring cuvettes and proceed with the light initiation Step s in table 2.
* Synthesis of the thyroxine-transferrin conjugate has been described in I.e. (2).
SPALT -solid phase antigen luminescence technique
The SPALT principle has been described in detail elsewhere (4, 5), and only the v riatipns are briefly described here. The SPALT assay can be set up s eithef a competitive or sequential assay, depending upon whether the solid phase antigen is added together with the first antibody and sample or after a pre-incubation of first antibody and sample. Tables 4 and 5 show competitive and sequential SPALT assays for caeruloplasmin and thyroxine respectively.
Assay semi-automation
The assays were originally set up in 55 x 12 mm polystyrene tubes which increased the time needed for pipetting and wash Steps s each tube had to be processed seperately. To increase throughput and reduce the workload assays were set up in either 20 or 60 well trays (cf. Abbott hepatitis kits). The wash Steps were carried out using a Pentawash multiple wash device (Abbott Laboratories) where 5 wells were washed simultaneously with 5 ml wash solution. The anti gen-antibody reaction was speeded up by incubating the trays on a horizontal rotator at 180 min"· 1 .
The improvement in precision, shortening of assay time and semiautomation of all methods more than compensated for the additional cost of buying the equipment. Moreover, the trays could be re-used after washing without the precision and accuracy of the assay being influenced.
Results
Comparison of a CELIA and ILMA for thyroxine binding globulin (TBG) Figure l shows Standard curves for a TBG-CELIA and a TBG-ILMA. Table 6 shows the relevant assay and quality control data. The antibody bound to the solid phase was the same in each case s was the label used, in this case diazoluminol. The TBG used for labelling was identical with that used for making up the Standards in both assays. Comparison between labelling using ILMA and IL-SA for ferritin äs examples Figure 2 shows three Standard curves using identical starting reagents. For the ILSA the second antibody (donkey anti-rabbit IgG) was labelled with diazoluminol (2), for the ILMAs both diazoluminol and N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide were used to label the second anti-ferritin antibody. Table 7 shows relevant data from all three curves, here with special reference to the sensitivity (Iowest detectable antigen level). Table 8 shows a comparison between three cortisol SPALT assays set up at the same time with the same reagents. The difference between the assays is that öne is oxidised at pH 8.6 to initiate the light reaction, the second with sodium hydroxide, directly after addition, and the third, after the solid phase has been left in contact with sodium hydroxide for 2 h. The assay flow sheet up until the light-reaction
Comparison of different pH values to initiale, the light reaction using a serum Cortisol SPALT äs an example
Step is shown in * These values represent the dynamic ränge for the CELIA and ILMA respectively. ** The CELIA, although giving a Standard curve, was unäble to measure serum samples, and was therefore abandonne'd. Target values in brackets. N *** The correlation coefficient and related data was determined from a comparison with the Henning TBG-RIA, resuits from 6 assays being used. The RIA values were entered äs x.
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Comparison between pymvate kinase and diazoluminol s labelfor the second antibody using a thyroxine SPALTE an example
The assay flow scheme has already been shown in table 5. Figure 3 shows Standard curves for both assays, the relevant assay data being shown in table 10. 
Clinical examples of routine luminescence immunoassay s -datafrom a caeruloplasmin SPALT, a Creactive protein ILSA and a ferritin ILMA
Figures 4 and 5 show typical Standard curves for caeruloplasmin and C-reactive protein respectively. The label for the caeruloplasmin SPALT was N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide, for C-reactive protein, diazoluminol. In both cases, the second antibody was labelled donkey anti-rabbit IgG. Table 11 shows clinical data obtained for different patient groups. The correlation between the ferritin assay here described and the radioimmunoassay used s its predecessor in the routine determination was excellent, (n = 91, r = 0.992, a yx = 0.071 and b yx = 0.999) when the same Standards were used in each assay. Here the radioimmunoassay values were entered s x, those from the ILMA s y. The r nge of the values used for this calculation were 5-570 μg/l for the RIA and 3-567 μ^ for the ILMA.~ 
Discussion
The aim of this paper has been to put into practice some of the experiments performed in the first two parts of this series (l, 2). A comparison of both labels and methods has been made using a wide variety of antigens äs ligands. Detailed clinical trials and evaluation results have been avoided, results being limited to a few assays, especially those shown in table 11.
The future of the luminescence immunoassay lies in its field of application, especially where its role äs a practical alternative to routine radioimmunoassays is concerned. The assays presented here represent the whole gamut of molecular size and concentration found in in-vitro clinical chemistry and endocrinology.
The results of the comparison between a CELIA and ILMA using the same label and components (diazoluminol and immobilised sheep anti TBG) shows the relative sensitivity and working ränge of the two assay types, here for thyroxine binding globulin. The larger working ränge of the ILMA agrees with the findings of Hunter (6) who compared radioimmunoassays and immunoradiometric assays for sensitivity and working ränge. The TBG CELIA, although giving a dose response curve when the Standards were dissolved in a buffer matrix, was unable to be used for measuring serum samples, where all values lay above the highest Standard. The combination of the relatively large sample volume (50 ) and contact between serum and label may be a crucial factor with the CELIA, äs the TBG ILMA, where a much smaller sample (l ) was used, and where serum and label did not come into contact, measured correctly. Similar problems were encountered with a thyroxine CELIA using larger serum volumes (50 ) and lowtiter low affinity antibodies (Gadow, unpublished results).
The comparison between the different labels is well demonstrated in the case of the ferritin assays (table 7, figure 2 ). Although the detection limits of free diazoluminol and N-(4-aminobutyl)-N-ethyI isoluminol hemisuccinamide were similar (2), the N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide label allowed an assay to be developed which was sensitive enough for routine use. This was probably due to the difference in the chemical coupling methods used, the N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide active ester being under neutral and mild reaction conditions, the diazo coupling taking place in alkaline solution over a period of several hours. The ferritin assays show the relative performance of ILMA and ILSA using the same label (here diazolu-minol). The dynamic ränge of the N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide labelled ferritin ILMA is far greater than that using diazoluminol äs label. This is reflected in the ratio between the number of counts in the highest Standard and those in the zero Standard, (see tab. 7). This ratio was 54:1 for N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide labelled anti ferritin and only 4.9:1 for diazoluminol labelled anti ferritin.
Various conditions have been described for the optimal conditions for light emission which ränge from initiation at pH 8-9 (7) via pH 13 (4) to initiation after Standing in alkaline solution for several minutes (8) to a few hours (Kohen, personal communication). The cortisol SPALT (see tab. 8 and 9) was used to compare the effect of pH and alkaline incubation on the light Output. Although the signal increases between pH 8 and pH 13 äs well äs between pH 13 when measured immediately and after 2 h Standing in sodiüm hydroxide, the signal to noise ratio, expressed in terms of the zero Standard (Bö) and unspecific binding (ÜB) increased only slightly.
The dynamic ränge of the assay, expressed äs the light signal given by the zero Standard and that given by the highest Standard, remained almost unchanged between pH 8 and pH 13, and was noticably reduced after prolonged alkaline incubation before light initiation.
The values of the control sera lay within the expected limits for all assays.
The thyroxine SPALT was used to demonstrate the use of bioluminescent and chemiluminescent labels. The bioluminescent SPALT had a larger dynamic ränge when compared with the diazoluminol labelled assay, and was potentially more sensitive, äs can be seen from the intercept values (tab. 10). Both assays measured correctly in terms of the control sera. Replacement of the diazoluminol labelled second antibody by one labelled with N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide gave rise to a similar increase in the dynamic ränge äs seen in the ferritin ILMA, so that for the routine assay, N-(4-aminobutyl)-N-ethyl isoluminol hemisuccinamide was chosen äs label. · · f As stated above, the proof of the assays is in their clinical routine application and examples have been presented for ferritin, C-reactive protein and caeruloplasmin, all of which are the only routine assay for these components. The results shown are taken from projects on patients with tumours and with Crohn's disease or ulcerative colitis (see tab. 11). The screening of blood donors is part of an ongoing routine procedure, especially upon new and regulär donors.
The mean precision within the workiiig ränge, here derived from compound precision profiles, was acceptable and comparable with commercial tests. A further advahtage of these tests was their suitability for paediatric use, the largest sample volume being 20 for ferritin.
One thing became clear when working with immobilised antibodies, and that was the necessity for partial purification of the native antisera before coupling to the solid phase. This was effected by precipitation of the -globulin fraction with 200 g/l polyethylene glycol (M r 6000) with resolution of the precipitate in 0.02 mol/1 phosphate buffer, pH 8. Sübse-quent passage over a DEAE-cellulose column was sufficient to give a product with acceptable purity.
To conclude, it has been shown that the application of luminescence immunoassays in routine in-vitro diagnosis is now possible, although the acceptance of such assays still depends upon the commercialisation of the methods.
